Laidlaw firm gets a court injunction over distributing false information about Relmada Inc

Laidlaw firm gets a court injunction over distributing false information about Relmada Inc

On December 11, 2015, Relmada Therapeutics Inc. officially reported that a Nevadan court had finally issued an order that would see Laidlaw & Company (UK) LTD desist from further distributing false and misleading proxy content about Relmada. The temporary order by the court was to take effect immediately and would enjoin Laidlaw& Company principles Mathew Eitner and James Ahern who Relmada Therapeutics Inc believes are behind the vice.
Relmada had previously announced that it had filed a lawsuit against Laidlaw and Messrs, following the release of the falsified materials. The company believes that the materials by Laidlaw were intended to take substantial control of Relmada Therapeutics Inc deliberately. Remalda Therapeutics is a clinical-stage firm, with the responsibility of manufacturing new versions of proven pain relieving drugs. Its high-quality products are attributed to its professional researchers who possess the first class knowledge and skills in medical research.
Laidlaw & Company (UK) LTD, on the other hand, is an investment bank and wealth management firm. Their services are felt throughout the US and the UK, and as part of the investment banking services, clients enjoy capital raising, placement of debts and mezzanine capital, financing of acquisitions, national exchange listing arrangement, and initial public offering. This firm also offers advisory services.
The company has been in operation for over 170 years. Currently, James Ahern is the company’s CEO, appointed in April 2011 after joining the company in 2010. Mathew has previously served as the Managing Director at Aegis Capital Corp. He has also served as Vice President of Casimir Capital.
On the other hand, James Ahern is the Managing Partner and Head of Capital market in the firm. Charged with the responsibility of financial arrangement for public and privately owned companies, he joined Laidlaw Company back in 2010.

One Response

  1. During his tenure, he has significantly grown Laidlaw marketing team and expanded the firm’s market share in the capital markets. The company is dedicated to reducing clinical development risks and costs while meeting developing medical needs. There is a vital need that the best quality writing paper can be able to do what they are supposed to do for them all along.